Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRA | P16234 | 6/20 | 0.39 |
| ▸ | KIT | P10721 | 3/20 | 0.39 |
| ▸ | MET | P08581 | 6/20 | 0.37 |
| ▸ | KDR | P35968 | 2/20 | 0.37 |
| ▸ | BTK | Q06187 | 5/20 | 0.36 |
| ▸ | EGFR | P00533 | 4/20 | 0.36 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.34 |
| ▸ | TEC | P42680 | 1/20 | 0.34 |
| ▸ | TXK | P42681 | 1/20 | 0.34 |
| ▸ | BLK | P51451 | 1/20 | 0.34 |
| ▸ | BMX | P51813 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.34 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.34 |
| ▸ | AXL | P30530 | 1/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5518881 | 0.90 | AAK1 (0.33) | PDGFRAKITMETKDRDDR2 | |
| SCHEMBL5508606 | 0.89 | PDGFRA (0.39) | PDGFRAKITMETKDRBTK | |
| SCHEMBL5509074 | 0.86 | FLT3 (0.33) | METAXLAAK1 | |
| SCHEMBL5506720 | 0.86 | MET (0.33) | METBTKEGFRERBB2TEC | |
| SCHEMBL14437285 | 0.86 | PDGFRA (0.41) | PDGFRAKITKDRBTKEGFR | |
| SCHEMBL5506278 | 0.80 | MET (0.36) | PDGFRAMETKDRDDR2AXL | |
| SCHEMBL5508442 | 0.79 | MEN1 (0.41) | PDGFRAKIT | |
| SCHEMBL5505043 | 0.78 | CLK4 (0.36) | AXL | |
| SCHEMBL5510840 | 0.77 | MET (0.36) | METBTKEGFRERBB2TEC | |
| SCHEMBL14437267 | 0.75 | CISD1 (0.40) | AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7253285-B2 | Thiazolinone 4-monosubstituted quinolines | HOFFMANN-LA ROCHE INC. (US) | 2007-08-07 | — | — | US | disclosed |
| US-20060063805-A1 | Thiazolinone 4-monosubstituted quinolines | CHEN LI | 2006-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063805-A1 | Thiazolinone 4-monosubstituted quinolines | CDK1, CDK14, CDK17 | PDGFRA 3386/4885KIT 2841/4885MET 1954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.